Moleculin Biotech, Inc.
MBRXNASDAQHealthcare● Active
$2.47
+$0.07(+2.92%)
Market Cap$2986526
P/E Ratio—
52W High$24
52W Low$1.79
Moleculin Biotech, Inc. (MBRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MBRX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$2.48
Est. -$1.69 · -46.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
MBRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$1.54 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$1.69 | -$2.48 | -46.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 20, 2026 | -$7.77 | $2.61 | +133.6% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$5.00 | -$3.25 | +35.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$9.75 | -$12.25 | -25.6% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$17.75 | -$17.25 | +2.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 21, 2025 | -$1.54 | -$0.37 | +76.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 11, 2024 | -$2.44 | -$2.85 | -16.8% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$1.54
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$2.48
EPS Est.
-$1.69
EPS Surpr.
-46.8%
Revenue
—
Q1 FY2026
Mar 20, 2026Beat
EPS Actual
$2.61
EPS Est.
-$7.77
EPS Surpr.
+133.6%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$3.25
EPS Est.
-$5.00
EPS Surpr.
+35.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$12.25
EPS Est.
-$9.75
EPS Surpr.
-25.6%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$17.25
EPS Est.
-$17.75
EPS Surpr.
+2.8%
Revenue
—
Q1 FY2025
Mar 21, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$1.54
EPS Surpr.
+76.0%
Revenue
—
Q4 FY2024
Nov 11, 2024Miss
EPS Actual
-$2.85
EPS Est.
-$2.44
EPS Surpr.
-16.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.87 | $-0.87 | $-0.87 | 1 |
| Q3 FY2026 | $-1.21 | $-1.13 | $-1.03 | 1 |
| Q2 FY2026 | $-1.65 | $-1.54 | $-1.42 | 1 |
| Q1 FY2026 | $-2.54 | $-2.33 | $-2.11 | 2 |
| Q4 FY2025 | $-9.98 | $-6.11 | $-2.23 | 2 |
| Q3 FY2025 | $-7.57 | $-6.58 | $-5.27 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -46.8% | $2.14 | $2.20 | +2.80% |
| ▲ Q1 FY2026 | Mar 20, 2026 | +133.6% | $2.06 | $2.06 | +0.00% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +35.0% | $12.19 | $11.35 | -6.89% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -25.6% | $15.55 | $16.55 | +6.43% |
| ▲ Q2 FY2025 | May 13, 2025 | +2.8% | $27.00 | $26.75 | -0.93% |
| ▲ Q1 FY2025 | Mar 21, 2025 | +76.0% | $27.25 | $27.25 | +0.00% |
| ▼ Q4 FY2024 | Nov 11, 2024 | -16.8% | $63.75 | $62.75 | -1.57% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -6.2% | $56.25 | $58.75 | +4.44% |
Q2 FY2026+2.80%
Report Date
May 14, 2026
EPS Beat/Miss
-46.8%
Price Before
$2.14
Price After
$2.20
Q1 FY2026+0.00%
Report Date
Mar 20, 2026
EPS Beat/Miss
+133.6%
Price Before
$2.06
Price After
$2.06
Q4 FY2025-6.89%
Report Date
Nov 13, 2025
EPS Beat/Miss
+35.0%
Price Before
$12.19
Price After
$11.35
Q3 FY2025+6.43%
Report Date
Aug 12, 2025
EPS Beat/Miss
-25.6%
Price Before
$15.55
Price After
$16.55
Q2 FY2025-0.93%
Report Date
May 13, 2025
EPS Beat/Miss
+2.8%
Price Before
$27.00
Price After
$26.75
Q1 FY2025+0.00%
Report Date
Mar 21, 2025
EPS Beat/Miss
+76.0%
Price Before
$27.25
Price After
$27.25
Q4 FY2024-1.57%
Report Date
Nov 11, 2024
EPS Beat/Miss
-16.8%
Price Before
$63.75
Price After
$62.75
Q3 FY2024+4.44%
Report Date
Aug 13, 2024
EPS Beat/Miss
-6.2%
Price Before
$56.25
Price After
$58.75
Avg Beat Reaction-1.95%
Avg Miss Reaction+3.03%
Beat Rate4 / 8 quarters
Largest Move-6.89% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MBRX ends December
Moleculin Biotech, Inc. (MBRX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-2.48 — missing the analyst consensus of $-1.69 by -46.8%. The next MBRX earnings date is expected around September 1, 2026.
Each quarter, investors track MBRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MBRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MBRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MBRX earnings · 5 questionsMoleculin Biotech, Inc.'s next earnings report is expected around September 1, 2026. MBRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MBRX historically reports after market close (AMC).
MBRX earnings datewhen is MBRX earningsMBRX next earnings datewhen does MBRX report earningsMBRX earnings calendar
▸ Source: FMP · Moleculin Biotech, Inc. SEC filings · US GAAP · Moleculin Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026